Overview
- Executive chairperson Kiran Mazumdar‑Shaw set a goal to put 20% of the world’s insulin users on Biocon products and said the company aims to be the insulin company of the world.
- Biocon is expanding output by doubling drug‑product capacity at its Malaysia insulin site by FY27 and is adding partnerships, including with U.S. nonprofit Civica, to widen access.
- The strategy leans on a market shift as Novo Nordisk, Eli Lilly, and Sanofi prioritize GLP‑1 therapies, which has strained pen and cartridge lines that insulin users still need.
- The company reports approvals in about 80 markets, has launched liraglutide in parts of Europe, won U.S. clearance for its generic liraglutide, and filed semaglutide in multiple countries.
- With India’s semaglutide patent lapse spurring a local price war, Biocon is focusing near‑term growth on the United States, Europe, and selected emerging markets where margins are stronger.